Background Development of in vivo biomarkers has shifted the diagnosis of Alzheimer's
disease (AD) from the later dementia stages of disease towards the earlier stages and has …

Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …

There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …

Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

Background Tauopathies are a class of neurodegenerative disorders characterized by
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …

Most patients with Alzheimer's disease present with amnestic problems; however, a
substantial proportion, over-represented in young-onset cases, have atypical phenotypes …

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects motor and
cognition functions. The etiology of Parkinson's disease remains largely unknown, but …

The clinical diagnosis of synucleinopathies, including Parkinson's disease (PD), dementia
with Lewy bodies (DLB), and multiple system atrophy (MSA), is challenging, especially at an …